Quartz·1 min read·medium
Eli Lilly is pushing its next-generation weight loss drug approval filing to early 2027
✦AI Summary
Eli Lilly has delayed the filing for its next-generation triple-hormone weight loss drug until early 2027. The company had previously suggested that an FDA approval request could occur as early as this year.
The company previously indicated it could seek FDA approval for the triple-hormone drug as early as this year
businesshealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in